German pharma lobby warns US price rules could impact local drug access

Pharma Deutschland warns that new US price rules may force firms to delay drug launches in Germany. The group says the nation risks falling behind in access.

The Pharma Deutschland association warned on February 11, 2026, that new drug price regulation in the United States USUS could lead pharmaceutical companies to demand higher prices for new drugs in Germany DEDE or to forgo launching them there. This response to the newly announced U.S. measures could delay or prevent the introduction of innovative medicines in Germany and Europe, affecting patient access to new treatments.
CEO of Germany's drug maker Bayer AG Bill Anderson poses for a portrait in front of the company's logo at the Bayer headquarters in Leverkusen, Germany, December 10, 2024. REUTERS/Wolfgang Rattay
CEO of Germany's drug maker Bayer AG Bill Anderson poses for a portrait in front of the company's logo at the Bayer headquarters in Leverkusen, Germany, December 10, 2024. REUTERS/Wolfgang Rattay